Last reviewed · How we verify
NITROFURANTOIN MACROCRYSTALS
At a glance
| Generic name | NITROFURANTOIN MACROCRYSTALS |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Drug class | Nitrofuran Antibacterial [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Nausea
- Emesis
- Anorexia
- Dyspnea on exertion
- Cough
- Malaise
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Drowsiness
- Vertigo
Serious adverse events
- Peripheral neuropathy (severe or irreversible)
- Chronic pulmonary hypersensitivity reaction
- Acute pulmonary hypersensitivity reaction
- Subacute pulmonary hypersensitivity reaction
- Hepatic necrosis
- Chronic active hepatitis
- Hepatitis
- Anaphylaxis
- Stevens-Johnson syndrome
- Pseudomembranous colitis
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (PHASE1)
- A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection (PHASE2)
- Role of Prophylactic Postoperative Antibiotics in HoLEP (PHASE4)
- Pediatric Pilonidal Sinus Surgical Treatment (NA)
- Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (PHASE3)
- Intravesical Gentamicin to Prevent Recurrent UTI (PHASE4)
- Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections (PHASE1)
- NextGen - Clinical Implication of Next Generation Sequencing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NITROFURANTOIN MACROCRYSTALS CI brief — competitive landscape report
- NITROFURANTOIN MACROCRYSTALS updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI